Recent Updates
Recently added Catalysts
AMIX Positive Sentiment Score: 75/100

Autonomix Medical, Inc. to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC

Key Takeaway: Autonomix Medical, Inc. has announced its participation in the 2024 Healthcare Virtual Summit hosted by Maxim Group LLC, with CEO Brad Hauser scheduled for a fireside chat. The company specializes in innovative technologies aimed at improving the diagnosis and treatment of diseases affecting the nervous system. Their leading-edge platform technology, featuring a catheter-based microchip sensing array, is designed to detect neural signals with enhanced sensitivity. While currently investigational, the technology holds promise for addressing various medical indications including chronic pain and pancreatic cancer.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in the 2024 Healthcare Virtual Summit offers visibility.
  • Innovative technology could significantly advance diagnosis and treatment.
  • First-in-class platform may improve detection sensitivity dramatically.
  • Potential to address multiple medical indications beyond current focus.

Full Press Release Details

Live webcast fireside chat on Tuesday, October 15th at 2:30 PM ET
THE WOODLANDS, TX, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, CEO of Autonomix, will participate in a fireside chat at the 2024 Healthcare Virtual Summit, presented by Maxim Group LLC on October 15, 2024 at 2:30 PM ET.
Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management. Maxim also plans to host several topical industry panels that promise to be timely and engaging. To attend, just sign up to become an M-Vest member and stay tuned for more updates
Click Here to Reserve Your Seat.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact

Tags

medical device company
2024 Healthcare Virtual Summit
Presented by Maxim Group LLC

Frequently Asked Questions

When is the Autonomix fireside chat scheduled?

The fireside chat is on October 15, 2024, at 2:30 PM ET.

Who will participate in the fireside chat?

Brad Hauser, CEO of Autonomix, will participate in the chat.

What technology does Autonomix focus on?

Autonomix specializes in innovative technologies for diagnosing nervous system diseases.

What is the aim of Autonomix's technology?

The technology aims to enable transvascular diagnosis and treatment of peripheral nerve diseases.

What conditions is Autonomix targeting initially?

The initial focus is on treating pain, particularly in pancreatic cancer.

Last updated: Oct 8, 2024